Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 13
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Conway, Jessica M. and Perelson, Alan S. 2015. Post-treatment control of HIV infection. Proceedings of the National Academy of Sciences, Vol. 112, Issue. 17, p. 5467.


    Shang, Hong-tao Ding, Ji-wei Yu, Shu-ying Wu, Tao Zhang, Qiu-li and Liang, Fu-jun 2015. Progress and challenges in the use of latent HIV-1 reactivating agents. Acta Pharmacologica Sinica, Vol. 36, Issue. 8, p. 908.


    2014. Translational Biology in Medicine.


    Boutimah, Fatima Eekels, Julia J.M. Liu, Ying Poi and Berkhout, Ben 2013. Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors. Antiviral Research, Vol. 98, Issue. 1, p. 121.


    Wightman, Fiona Lu, Hao K. Solomon, Ajantha E. Saleh, Suha Harman, Andrew N. Cunningham, Anthony L. Gray, Lachlan Churchill, Melissa Cameron, Paul U. Dear, Anthony E. and Lewin, Sharon R. 2013. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS, Vol. 27, Issue. 18, p. 2853.


    Cardozo, E. Fabian Vargas, Cesar A. and Zurakowski, Ryan 2012. 2012 IEEE 51st IEEE Conference on Decision and Control (CDC). p. 4924.

    Lafeuillade, Alain 2012. Eliminating the HIV Reservoir. Current HIV/AIDS Reports, Vol. 9, Issue. 2, p. 121.


    Karn, Jonathan 2011. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Current Opinion in HIV and AIDS, Vol. 6, Issue. 1, p. 4.


    Kim, Young Kyeung Mbonye, Uri Hokello, Joseph and Karn, Jonathan 2011. T-Cell Receptor Signaling Enhances Transcriptional Elongation from Latent HIV Proviruses by Activating P-TEFb through an ERK-Dependent Pathway. Journal of Molecular Biology, Vol. 410, Issue. 5, p. 896.


    Peek, Gregory W. and Tollefsbol, Trygve O. 2011. The transposon-driven evolutionary origin and basis of histone deacetylase functions and limitations in disease prevention. Clinical Epigenetics, Vol. 2, Issue. 2, p. 97.


    Janneh, O. Bray, P. G. Jones, E. Wyen, C. Chiba, P. Back, D. J. and Khoo, S. H. 2010. Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. Journal of Antimicrobial Chemotherapy, Vol. 65, Issue. 5, p. 906.


    Keedy, Kara S. and Margolis, David M. 2010. Therapy for persistent HIV. Trends in Pharmacological Sciences, Vol. 31, Issue. 5, p. 206.


    Roy, Upal Chakravarty, Geetika Honer Zu Bentrup, Kerstin and Mondal, Debasis 2009. Montelukast Is a Potent and Durable Inhibitor of Multidrug Resistance Protein 2-Mediated Efflux of Taxol and Saquinavir. Biological & Pharmaceutical Bulletin, Vol. 32, Issue. 12, p. 2002.


    ×
  • Expert Reviews in Molecular Medicine, Volume 11
  • 2009, e6

Pharmaceutical approaches to eradication of persistent HIV infection

  • Mary-Catherine Bowman (a1), Nancie M. Archin (a1) and David M. Margolis (a1)
  • DOI: http://dx.doi.org/10.1017/S1462399409000970
  • Published online: 01 February 2009
Abstract

Highly active antiretroviral therapy (HAART) has markedly decreased morbidity and mortality in human immunodeficiency virus type 1 (HIV-1)-infected individuals in the developed world. Successful therapy often results in stable plasma levels of HIV-1 RNA below the limits of detection of commercial assays. Nonetheless, HIV-1 has not been cured by HAART. The causes of persistence of HIV infection in the face of current therapy appear to be multifactorial: latent but replication-competent provirus in resting CD4+ T cells, cryptic viral expression below the limits of detection of clinical assays, and viral sanctuary sites might all contribute to persistence. Clearance of HIV infection will almost certainly require a multimodality approach that includes potent suppression of HIV replication, therapies that reach all compartments of residual HIV replication and depletion of any reservoirs of persistent, quiescent proviral infection. This review highlights the basic mechanisms for the establishment and maintenance of viral reservoirs and pharmaceutical approaches towards their elimination.

Copyright
Corresponding author
*Corresponding author: David Margolis, 3302 Michael Hooker Research Bldg, CB#7435, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7435, USA. Tel: +1 919 966 6388; Fax: +1 919 966 0584; E-mail: dmargo@med.unc.edu
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1F.J. Palella Jr. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 338, 853-860

2A.S. Perelson (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586

3D.C. Nickle (2003) Importance and detection of virus reservoirs and compartments of HIV infection. Current Opinion in Microbiology 6, 410-416

4J.N. Blankson , D. Persaud and R.F. Siliciano (2002) The challenge of viral reservoirs in HIV-1 infection. Annual Review of Medicine 53, 557-593

5T. Pierson , J. McArthur and R.F. Siliciano (2000) Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annual Review of Immunology 18, 665-708

7A.S. Perelson (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191

8D.D. Ho (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126

9X. Wei (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122

10M.A. Polis (2001) Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 358, 1760-1765

11M. Louie (2003) Determining the relative efficacy of highly active antiretroviral therapy. Journal of Infectious Diseases 187, 896-900

12D.R. Kuritzkes (2007) Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. Journal of Infectious Diseases 195, 1169-1176

13D.D. Ho , T.R. Rota and M.S. Hirsch (1986) Infection of monocyte/macrophages by human T lymphotropic virus type III. Journal of Clinical Investigation 77, 1712-1715

14S. Gartner (1986) The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233, 215-219

15S. Sonza (2001) Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. Aids 15, 17-22

16M. Markowitz (2007) Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. Journal of Acquired Immune Deficiency Syndromes 46, 125-133

17J.M. Murray (2007) Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. Aids 21, 2315-2321

18S. Bonhoeffer (1997) Virus dynamics and drug therapy. Proceedings of the National Academy of Sciences of the United States of America 94, 6971-6976

19M. Stevenson (2003) HIV-1 pathogenesis. Nature Medicine 9, 853-860

20A.T. Haase (2005) Perils at mucosal front lines for HIV and SIV and their hosts. Nature Reviews Immunology 5, 783-792

22S.L. Heath (1995) Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377, 740-744

23T.B. Geijtenbeek (2000) Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100, 575-585

24W. Cavert (1997) Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276, 960-964

25W.S. Hlavacek (2000) Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 97, 10966-10971

26J.A. Garcia (2006) HIV-1 dynamics at different time scales under antiretroviral therapy. Journal of Theoretical Biology 238, 220-229

27W.S. Hlavacek (2002) Retention of antigen on follicular dendritic cells and B lymphocytes through complement-mediated multivalent ligand-receptor interactions: theory and application to HIV treatment. Mathematical Biosciences 176, 185-202

28B.F. Keele (2008) Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. Journal of Virology 82, 5548-5561

29D. Finzi and R.F. Siliciano (1998) Viral dynamics in HIV-1 infection. Cell 93, 665-671

30M. Di Mascio (2003) In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months. Journal of Virology 77, 2271-2275

31G. Dornadula (1999) Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Journal of the American Medical Association 282, 1627-1632

32V. Muller , J.F. Vigueras-Gomez and S. Bonhoeffer (2002) Decelerating decay of latently infected cells during prolonged therapy for human immunodeficiency virus type 1 infection. Journal of Virology 76, 8963-8965

33M.C. Strain (2003) Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proceedings of the National Academy of Sciences of the United States of America 100, 4819-4824

35S. Palmer (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 105, 3879-3884

36T.W. Chun (1995) In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nature Medicine 1, 1284-1290

37T.W. Chun (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188

38T.W. Chun (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 94, 13193-13197

39D. Finzi (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300

40J.K. Wong (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295

41T.W. Chun (2005) HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. Journal of Clinical Investigation 115, 3250-3255

42J.D. Siliciano (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Medicine 9, 727-728

43J.D. Siliciano and R.F. Siliciano (2004) A long-term latent reservoir for HIV-1: discovery and clinical implications. Journal of Antimicrobial Chemotherapy 54, 6-9

44M.C. Strain (2005) Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. Journal of Infectious Diseases 191, 1410-1418

45T.W. Chun (2007) Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. Journal of Infectious Diseases 195, 1762-1764

46D.M. Margolis and N.M. Archin (2007) Eliminating persistent HIV infection: getting to the end of the rainbow. Journal of Infectious Diseases 195, 1734-1736

47S.A. Williams and W.C. Greene (2005) Host factors regulating post-integration latency of HIV. Trends in Microbiology 13, 137-139

48W.J. Swiggard (2005) Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. Journal of Virology 79, 14179-14188

49S. Swingler (2003) HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 424, 213-219

50D.G. Brooks (2001) Generation of HIV latency during thymopoiesis. Nature Medicine 7, 459-464

51J.M. Brenchley (2004) T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. Journal of Virology 78, 1160-1168

52J.R. Bailey (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. Journal of Virology 80, 6441-6457

53T.W. Chun (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nature Medicine 6, 757-761

54T. Zhu (2002) Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. Journal of Virology 76, 707-716

55O. Lambotte (2000) Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 23, 114-119

56P.J. Ellery (2007) The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. Journal of Immunology 178, 6581-6589

57M. Otero (2003) Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. AIDS Research and Human Retroviruses 19, 1097-1103

58A.M. Mowat and J.L. Viney (1997) The anatomical basis of intestinal immunity. Immunological Reviews 156, 145-166

59R.S. Veazey (1998) Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280, 427-431

60T.W. Chun (2008) Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. Journal of Infectious Diseases 197, 714-720

61M.A. Polis (2003) Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen. Aids 17, 1167-1172

62J.E. Bell (2004) An update on the neuropathology of HIV in the HAART era. Histopathology 45, 549-559

63S. Kramer-Hammerle (2005) Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Research 111, 194-213

64O. Lambotte (2005) Persistence of replication-competent HIV in the central nervous system despite long-term effective highly active antiretroviral therapy. Aids 19, 217-218

65J.K. Craigo (2004) Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. AIDS Research and Human Retroviruses 20, 1196-1209

66G. Nunnari (2002) Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. Aids 16, 39-45

67D. Marras (2002) Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nature Medicine 8, 522-526

68J.A. Winston (2001) Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. New England Journal of Medicine 344, 1979-1984

69D.H. Hamer (2004) Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it. Current HIV Research 2, 99-111

70R.T. Davey Jr. (1999) A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. Journal of Infectious Diseases 179, 849-858

71J.A. Kovacs (1995) Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. New England Journal of Medicine 332, 567-575

72J.A. Kovacs (2005) Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. Journal of Clinical Investigation 115, 2139-2148

75T.W. Chun (1999) Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature Medicine 5, 651-655

76M. Dybul (2002) Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. Journal of Infectious Diseases 185, 61-68

77J. Kulkosky (2002) Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. Journal of Infectious Diseases 186, 1403-1411

78H.J. Stellbrink (2002) Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). Aids 16, 1479-1487

79I. Sereti (2005) In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. Journal of Clinical Investigation 115, 1839-1847

81J.M. Prins (1999) Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. Aids 13, 2405-2410

82R.M. van Praag (2001) OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. Journal of Clinical Immunology 21, 218-226

84A. Llano (2001) Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals. Journal of Virology 75, 10319-10325

85O. Ducrey-Rundquist , M. Guyader and D. Trono (2002) Modalities of interleukin-7-induced human immunodeficiency virus permissiveness in quiescent T lymphocytes. Journal of Virology 76, 9103-9111

86G. Lehrman (2004) Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. J Acquir Immune Defic Syndr 36, 1103-1104

87F.X. Wang (2005) IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. Journal of Clinical Investigation 115, 128-137

89S.A. Trushin (2005) Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. Journal of Virology 79, 9821-9830

90J. Kulkosky (2001) Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98, 3006-3015

91J. Kulkosky (2004) Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents. AIDS Research and Human Retroviruses 20, 497-505

92S.A. Williams (2004) Prostratin antagonizes HIV latency by activating NF-kappaB. Journal of Biological Chemistry 279, 42008-42017

93A. Biancotto (2004) Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. Journal of Virology 78, 10507-10515

94R.J. Gulakowski (1997) Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Research 33, 87-97

95P.A. Wender , J.M. Kee and J.M. Warrington (2008) Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science 320, 649-652

96E. Melloni (1987) Protein kinase C activity and hexamethylenebisacetamide-induced erythroleukemia cell differentiation. Proceedings of the National Academy of Sciences of the United States of America 84, 5282-5286

98V. Zoumpourlis and D.A. Spandidos (1992) Hexamethylene bisacetamide stimulates the expression of human immunodeficiency virus long terminal repeat sequences in rat and human fibroblasts. Anti-Cancer Drugs 3, 163-167

100S.K. Choudhary , N.M. Archin and D.M. Margolis (2008) Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. Journal of Infectious Diseases 197, 1162-1170

104V. Klichko (2006) Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. Journal of Virology 80, 4570-4579

105T.L. Sung and A.P. Rice (2006) Effects of prostratin on Cyclin T1/P-TEFb function and the gene expression profile in primary resting CD4+ T cells. Retrovirology 3, 66

106R. Pearson (2008) Epigenetic Silencing of HIV Transcription by Formation of Restrictive Chromatin Structures at the Viral LTR Drives the Progressive Entry of HIV into Latency. Journal of Virology 82, 12291-12303

107J. Brady and F. Kashanchi (2005) Tat gets the “green” light on transcription initiation. Retrovirology 2, 69

108N. He , A.C. Pezda and Q. Zhou (2006) Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. Molecular and Cellular Biology 26, 7068-7076

109P.A. Arlen (2006) Rapid expression of human immunodeficiency virus following activation of latently infected cells. Journal of Virology 80, 1599-1603

110L.S. Weinberger (2005) Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122, 169-182

111J. Cho , M.E. Parks and P.B. Dervan (1995) Cyclic polyamides for recognition in the minor groove of DNA. Proceedings of the National Academy of Sciences of the United States of America 92, 10389-10392

112J.J. Coull (2002) Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. Journal of Virology 76, 12349-12354

113L. Ylisastigui (2004) Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. Journal of Infectious Diseases 190, 1429-1437

114D. Demonte (2004) Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochemical Pharmacology 68, 1231-1238

115C.J. Phiel (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Journal of Biological Chemistry 276, 36734-36741

116C. Moog (1996) Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. Journal of General Virology 77, 1993-1999

117M. Witvrouw (1997) Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. AIDS Research and Human Retroviruses 13, 187-192

118L. Ylisastigui (2004) Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. Aids 18, 1101-1108

119G. Lehrman (2005) Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366, 549-555

120N.M. Archin (2008) Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. Aids 22, 1131-1135

121L.E. Jones and A.S. Perelson (2007) Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 45, 483-493

122J.D. Siliciano (2007) Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. Journal of Infectious Diseases 195, 833-836

123N. Sagot-Lerolle (2008) Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. Aids 22, 1125-1129

124P.A. Marks and R. Breslow (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnology 25, 84-90

125M.C. Bowman (2008) Inhibition of HIV fusion with multivalent gold nanoparticles. Journal of the American Chemical Society 130, 6896-6897

126P.E. Kennedy (2006) Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. Journal of Leukocyte Biology 80, 1175-1182

127E.A. Berger , B. Moss and I. Pastan (1998) Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART. Proceedings of the National Academy of Sciences of the United States of America 95, 11511-11513

128C. McCoig (1999) An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. Proceedings of the National Academy of Sciences of the United States of America 96, 11482-11485

L Geeraert , G Kraus , RJ Pomerantz . (2008) Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annual Review of Medicine. 59, 487-501.

S.A. Williams and W.C. Greene (2007) Regulation of HIV-1 latency by T-cell activation. Cytokine 39, 63-73

G. He , L. Ylisastigui and D.M. Margolis (2002) Chromatin Regulation of HIV-1 Expression. DNA and Cell Biology 21, 697-705

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×